Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

NCT06773936 | Enrolling By Invitation Phase 2 DMC FDA Drug

• 2 other identifiers: 21CTP.LEUK01CABL001AUS11R
• Study Type: interventional
• Target: 55
• Locations: 1 country
• Sites: 8

Brief Summary

This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual approach for Ph+ALL?"

Conditions

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia; CD19+ Acute Leukemia

Keywords

PH+ALL; ALL; Philadelphia Chromosome Positive; Acute Lymphoblastic Leukemia

Outcome Measures

Primary Outcomes (1)

• Major molecular remission by polymerase chain reaction for BCR-ABL

  Major molecular remission (MMR), also known as MR3.0, is defined as BCR-ABL transcript levels (expressed as a percentage compared with the ABL control gene) ≤ 0.1% based on PCR at day 85.

  Up to 100 days after treatment start

Secondary Outcomes (14)

• Rate of Complete Remission (with and without complete count recovery, CR/CRi)

  Up to 100 days after treatment start

• Disease-free Survival

  Up to 5 years.

• Overall Survival

  Up to 5 years

• Incidence of Adverse Events

  Up to 5 years

• Rate of Measurable Residual Disease Remission by Flow Cytometry (MRD Flow)

  Up to 100 days after treatment start

Interventions

Induction Phase DRUG

Asciminib, Dasatinib, Prednisone, and Methotrexate

Re-Induction Phase DRUG

Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone

Post-Remission DRUG

Blinatumomab, Dasatinib, Methotrexate and Dexamethasone

Maintenance DRUG

Asciminib, Dasatinib, Prednisone, and Methotrexate

Eligibility Criteria

• Age: 60 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants must have a new diagnosis of Philadelphia chromosome positive (Ph+) ALL by cytogenetics, FISH, or polymerase chain reaction (PCR). Diagnostic specimens must be submitted to the site's local CLIA-approved cytogenetics laboratory and results (cytogenetics, FISH, or PCR) must confirm Ph status prior to registration.
• Participants must have BCR-ABL status (p190 or p210) performed but results don't need to be back prior to Step 1 registration.
• Participants must have evidence of CD19+ ALL in their marrow or peripheral blood with at least 20% lymphoblasts present in blood or bone marrow collected within 28 days prior to registration. Immunophenotyping of the blood or marrow lymphoblasts must be performed to determine lineage. Appropriate marker studies including CD19 (B cell) must be performed. If a bone marrow aspirate cannot be obtained despite an attempt (dry tap), appropriate Immunohistochemistry (IHC) testing, including CD19, must be performed on the bone marrow biopsy to determine lineage. Participants with only extramedullary disease in the absence of bone marrow or blood involvement are not eligible. CD19+ is defined as \> 20% expression by flow cytometry or IHC.
• Participants must have recovered from any prior major surgery adverse effects within 14 days prior to registration, to the satisfaction of the local investigator.
• Participants must be ≥ 60 years old, or, if participants are under 60 years of age, they are not suitable for standard intensive induction chemotherapy at the discretion of the local investigator or must have refused standard intensive chemotherapy.
• Participants must have a lumbar puncture to determine CNS involvement of ALL within 14 days prior to registration. Note that intrathecal methotrexate administered during the pre-study lumbar puncture may count as the first dose of intrathecal therapy required as part of the study.
• Participants must have completed medical history and physical exam within 28 days prior to registration.
• Participants must have Zubrod/ECOG Performance Status of 0-3.
• Participants with extramedullary disease at diagnosis must have an MRI or CT scan with contrast of chest, neck, abdomen, pelvis, or whole body to obtain baseline values within 28 days prior to registration.
• Participants must have adequate pancreatic and liver function within 14 days prior to registration
• Participants must have a calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault Formula. This specimen must have been drawn and processed within 14 days prior to registration.
• Participants must have adequate cardiac function.
• Participants must be able to take oral medications and comply with the oral regimen.
• Participants with history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to registration, if indicated.
• Participants with known history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration.

You may not qualify if:

• Participants must not have known lymphoid blast crisis of CML or have received previous TKI therapy for their CML.
• Participants must not have received any prior chemotherapy, investigational agents, radiation therapy, or other therapy for the treatment of ALL other than the following for a maximum of 7 days: FDA-approved TKI therapy, steroids, hydroxyurea, leukapheresis, and intrathecal chemotherapy.
• Participants must not be receiving any immunosuppressive therapy.
• Participants must not have received a prior autologous or allogeneic hematopoietic stem cell transplant.
• Participants must not have received any monoclonal antibody therapy within 42 days prior to registration.
• Participants must not have a history or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, active ALL in the CNS confirmed by CSF analysis, or other significant CNS abnormalities.
• Participants must not have a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen (in the opinion of the treating physician).
• Participants must not have systemic fungal, bacterial, viral or other infection that is not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment) as determined by the local investigator.
• Participants must not have clinically significant pericardial effusion, ascites or pleural effusion based on chest CT or x-ray or echocardiogram within 28 days prior to registration. Exceptions: if the effusion is suspected to be related to leukemia, the participant may have pericardial effusion ≤ Grade 2 or pleural effusion ≤ Grade 1.
• Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 24 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen.
• Participants must not have clinically significant autoimmune disease.
• Participants must not be receiving any proton pump inhibitors at the time of registration.
• Participants must not have impairment of gastrointestinal function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome). Participants who have had a gastrectomy are eligible.
• Participants must not have a history of or current acute pancreatitis, chronic pancreatitis, or any ongoing pancreatic disease.
• Participant must not have uncontrolled intercurrent illness.

Sponsors & Collaborators

• SWOG Cancer Research Network: lead
• Novartis Pharmaceuticals: collaborator

Study Sites (8)

UC Irvine Medical Center

Orange, California, 92868, United States

Location

Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042, United States

Location

University of Rochester Medical Center

Rochester, New York, 14642, United States

Location

Duke University Medical Center

Durham, North Carolina, 27710, United States

Location

University of Cincinnati Cancer Ctr-UC Medical Ctr

Cincinnati, Ohio, 45267, United States

Location

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States

Location

Baptist Memorial Health Care

Memphis, Tennessee, 38120, United States

Location

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions

Maintenance

Condition Hierarchy (Ancestors)

Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Health Care Facilities Workforce and Services

Study Officials

• Anjali S Advani

  SWOG Network Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 8, 2025
• First Posted: January 14, 2025
• Study Start (Estimated): May 15, 2026
• Primary Completion (Estimated): May 1, 2029
• Study Completion (Estimated): July 1, 2033
• Last Updated: May 6, 2026

Record last verified: 2026-05

Locations

US (8)